-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:CGNX公布了2026年第一季度稳健的业绩,营收达2.68亿美元(同比增长24%),超出市场预期2200万美元;调整后每股收益为0.34美元(同比增长113%),超出预期0.09美元。利润率持续扩张,调整后EBITDA利润率达到26.9%(同比增长1010个基点),营业利润率飙升至22.3%(同比增长1020个基点),展现出卓越的运营杠杆效应。我们认为这验证了公司多元化战略的正确性,并表明工业自动化行业的复苏势头正在增强。强劲的现金流产生能力带来了4230万美元的自由现金流(同比增长11%),公司已向股东返还了1.13亿美元,目前持有6.22亿美元现金,且无任何债务。 第二季度业绩指引显示,公司将继续保持强劲增长势头,预计营收为2.8亿美元至3亿美元,调整后每股收益为0.40美元至0.44美元(中值同比增长68%),高于市场普遍预期的0.30美元。我们认为,凭借技术领先优势、卓越运营和终端市场多元化,CGNX在整个自动化周期中都拥有持续优异的业绩表现。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.